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Abstract

Gliomas, which are brain tumors that arise from glial cells, are some of the most aggressive and lethal types
of tumors. These brain tumors are difficult to treat because not enough information regarding the mutations
present in these tumors exists. This project studies effects of a p53 mutation on Drosophila glioma
progression and then will test to see if this results in resistance to current chemotherapy. The main goal of
this endeavor is to investigate the numerous defects occurring at the cellular and biochemical level in
gliomas, which will give insight into why these types of tumors are so difficult to treat. Additionally, this
document also discusses some promising chemotherapeutic agents found through a drug screen project.
The effects of five different Tyrosine Kinase inhibitors on glioma development are presented here.
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Preface: In September of 2017, I began working in Dr. Kango-Singh’s lab as a part of the
drug screen team. This project aims to look at the effects of a slew of possible
chemotherapeutic agents on glioma development. As a member of this group, I had the
opportunity to learn many lab techniques, how to work with fruit flies and gain a better
understanding of this type of cancer and its mechanisms. Due to my interest in the subject
of brain tumor research, I decided to apply to the Berry Summer Thesis Institute in hopes
of working on a project to write my honors thesis about. With the help and guidance of
Dr. Kango-Singh, I began working on a stand-alone project in addition to the chemical
screen. This new project involved inducing a p53 mutation in a Drosophila glioma model
in order to explore how this specific mutation affects tumor progression. We had planned
to treat these tumors with various Tyrosine Kinase inhibitors to see if this mutation
contributed to the tumor’s resistance to therapy. Although the summer provided a
successful start to the project, which involved some initial tests, we were not able to
complete all of our goals. COVID-19 shut down our lab work, as the university halted inperson undergraduate research. Even though my thesis project was cut short, there were
multiple promising findings with respect to the drug screen project, which I will discuss
in this paper. Furthermore, I have compiled the findings of numerous papers and articles
in order to write a literature review regarding the p53 mutation and gliomas.
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Drug Screen
1. Background
Brain cancer, specifically glioblastoma multiforme (GBM) is one of the most deadly
and devastating diseases. Median survival after diagnosis is about 15 months, even after
surgery, radiation and chemotherapy. Patients are often plagued by headaches, seizures
and other neurological symptoms, along with the side effects of treatments. In order to
properly treat this disease, it is necessary to develop and identify more effective, targeted
treatments.

Fig. 1 Coronal T1 C+ MRI of a patient
suffering from a “butterfly” glioma
(GBM that has spread to both
hemispheres of the brain). Patients
presenting with bilateral involvement
typically have even worse survival
outcomes and usually die within a few
months following diagnosis, despite
treatment.
Image retrieved from: Gaillard, Frank.
(2016). Glioblastoma NOS (butterfly
morphology). Radiopaedia.
https://radiopaedia.org/cases/glioblastom
a-nos-butterfly-morphology?lang=us

In an effort to identify possible treatment options for glioma patients, the KangoSingh lab developed a drug screen which involves testing the effects of many different
chemicals at varying concentrations on fruit fly gliomas. This involved creating a genetic
cross that would induce a feasible glioma model. This was accomplished by inducing the
two most frequently occurring human glioma mutations into the Drosophila model. The
Ras/MAPK signal transduction pathway was altered by inducing a RasV12 mutation,
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which is one commonly found in human cancers. PtenRNAi was co-expressed with this
mutation in an effort to better mimic human tumors. When Pten functions normally, it
plays a role in growth regulatory pathways as a tumor suppressor. However, since Pten
was eliminated, its tumor suppressor abilities were lost, and results in tumor
development. The combination of this mutation and RasV12 drove tumor development and
progression to create an effective glioma model. The PtenRNAi ; RasV12 stock were crossed
with the repo GAL4 UAS GFP stock, which drives expression of UAS-linked transgenes
in the glial cells in developing larvae. The GFP allows for tracking glial cells using
fluorescent microscopy imaging, as glial cells glow green due to expression of the GFP
(Green Fluorescence Protein). Tyrosine Kinase inhibitors were fed to the Drosophila
larvae, and tumor progression/growth was analyzed.

Fig. 2 Mutations within Ras/MAPK and PI3K/ Pten
can drive tumorigenesis and tumor growth.
( https://www.researchgate.net/figure/Ras-signalingpathways-Ras-signaling-is-involved-in-numerouscellular-functions_fig1_266582872)
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All of the drugs used in this project are classified as Tyrosine Kinase inhibitors.
They are also approved by the FDA for the treatment of certain cancers as well as other
dangerous diseases. Tyrosine Kinases are a family of enzymes which function as part of a
signaling cascade and are known to mediate cellular processes important to the
prevention of cancer. They do this by selectively phosphorylating substrates. Tyrosine
kinases play a role in cell metabolism, migration, apoptosis, proliferation and
differentiation. Certain mutations can lead to loss of these functions and the development
of cancer. Furthermore, cancerous mutations in this cascade can contribute to
angiogenesis as well, making tumors more vascularized [21].
Tyrosine kinases and tyrosine phosphatases regulate tyrosine kinase phosphorylation,
however, in mutated cells, this antagonistic control becomes dysregulated. Cancers such
as glioblastoma, non-small cell lung cancer, multiple myeloma and ovarian cancer are
known to result, in part due to mutations within the extracellular domain. Such mutations
lead to constitutive activity of receptor tyrosine kinase and, in turn, rapid proliferation of
mutated cells. Another way in which tyrosine kinases become over-expressed or
abnormally expressed results from autocrine-paracrine signaling. Essentially, this
feedback loop becomes overstimulated and there is over-expression of the ligand [21].
A mutation present in about 40 percent of gliomas lies in the epidermal growth factor
receptor (EGFR). Although there are numerous mutations present in this type of tumor,
this specific one is known to enhance tumorigenesis in humans as a result of
amplification. Additionally, it is believed to be a biomarker of resistance in certain types
of tumors. In terms of tumor development, EGFR functions in a signaling cascade which
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regulates the activation of genes within the nucleus important for cell differentiation,
proliferation and survival [28].

Fig. 3 EGFR regulates numerous pathways and subsequently,
many major cellular processes.
(https://www.sinobiological.com/pathways/egfr-signalingpathway)

When a

ligand attaches to the EGFR, EGFR protein dimerizes and activates the receptor complex,
beginning the signaling cascade. Two important pathways, PI3K and RAS-MAPK are
modulated via a downstream signaling cascade by EGFR. These both function to promote
cell proliferation, metastasis and the inhibition of programmed cell death. Therefore,
amplification or mutations within this gene can have cancerous effects [32]. The reason
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that EGFR is important to this study is the fact that many of the drugs tested are known
EGFR inhibitors. EGFR inhibitors work to block this protein’s activity and slow the
proliferation of cancer cells.
Promising Drugs Identified
Saracatinib is an oral chemotherapy drug used for the treatment of chronic
myeloid leukemia due to its action as an Abl and Src inhibitor. It was developed by
AstraZeneca and is approved by the FDA. These two protein kinases are frequently
overexpressed in leukemia cells. This drug is also being tested for the treatment of
various bone cancers such as osteosarcoma because it is known to inhibit Src kinasemediated osteoclast bone resorption [16]. The role Saracatinib plays in modifying various
cellular processes is still being investigated. For example, it was recently discovered that
Saracatinib inhibits the Fyn Kinase as well, which also falls into the family of Tyrosine
kinases and is a known oncogene. Due to the fact that Fyn mediates beta-amyloid
toxicity, Saracatinib is being tested as potential treatment for Alzheimer’s disease [34].
For the purposes of this experiment, Saracatinib was tested for its effect on
gliomas. In one study, it was found that SRC activity is increased in GBM brain samples
as compared to healthy brain tissue. Interestingly, the rise in activity is not due to
mutations or overexpression, but rather as a result of higher levels of growth factor
receptors on the surface of the cells. Another reason for this amplification is the
activation of integrins which in turn activate SFKs. SFKs function as tyrosine kinases and
mediate signaling within the cell. According to various GBM cell lines, the dysregulation
of SFK affects cell adhesion. SFK dysregulation is also believed to play a role in cancers
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that metastasize to the brain. In studies where SRC was inhibited, GBM, in addition to
numerous other types of cancers, exhibited lower levels of cell proliferation. This finding
points to the role that an SRC inhibitor, such as Saracatinib, may play in preventing the
proliferation of cancerous cells within the brain [2].

Fig. 4 SRC mediates numerous cellular processes, including angiogenesis,
survival, proliferation and motility. If dysregulated, this pathway can
contribute to rapid division of cancerous cells, tumor development and
metastasis.

Gefitinib (brand name:Iressa) is also approved by the FDA to be used for the
treatment of various cancers, specifically those affecting the breast and lung. It was also
developed by AstraZeneca as a Tyrosine Kinase inhibitor [18]. Gefitinib inhibits EGFR
by selectively binding to its domain, therefore interfering with autophosphorylation and
disrupting the signaling cascade. This disruption leads to decreased cell proliferation and
increased rates of apoptosis. Additionally, Gefitinib plays a role in preventing
angiogenesis, which is the growth of new blood vessels. Tumors responding positively to
this drug may become less vascular.
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Fig. 5 The process of angiogenesis
increases blood supply to tumors
and affects tumor growth. Drugs
that inhibit angiogenesis may
shrink tumors due to decreased
blood supply and subsequent
hypoxia. Unfortunately, tumors
can become resistant to these
efforts and continue to grow.
(https://www.cell.com/trends/canc
er/fulltext/S2405-8033(16)301856)

In a study done in 2018, GBM patients with either an EGFR mutation, PTEN
mutations or both upon biopsy were treated with Gefitinib. Although side effects were
common, patients treated with Gefitinib fared better than others. EGFR+ve/PTEN–ve
patients’ survival rates were significantly higher after being administered 250–500
mg/day of the drug over a span of several months. After tumor resection, several patients
with remaining tumor had stable scans or shrunken tumors after taking Gefitinib [4].
Another study, focusing on recurrent gliomas suggests that Gefitinib in combination with
other chemotherapeutic drugs may target EGFR mutations, improving patient survival.
However, this same study discussed the need for further research into this drug and the
pathways it may affect in order to target specific mutations [24].

Fig. 6 When Gefitinib binds to the receptor, it
can inhibit numerous cellular processes,
including cell proliferation, invasion,
angiogenesis, metastasis and the inhibition of
apoptosis. All of these actions can have anticancer effects by preventing the development
and migration of cancer cells.
(https://err.ersjournals.com/content/19/117/186
)
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Genistein is a phytoestrogen that exhibits anti-cancer effects. Genistein is
commonly found in soy and in countries with soy-rich diets, people are less likely to
develop breast or prostate cancer. Although its exact mechanism is unknown, the
chemical is believed to target MAPK and PI3K/Akt (important targets for GBM therapy)
pathways among a few others [29].
In one study involving GBM and medulloblastoma (brain tumor located in the
medulla, typically a childhood cancer), Genistein was found to arrest cell growth in
cancerous cells. The growth arrest happened during the transition from G2 to M stages of
the cell cycle, which halted mitosis. The drug also inhibited TR- and TERT mRNA,
which decreased telomerase activity. Telomerase lengthens telomeres, preventing
degradation of the chromosome. Even though Genistein damaged the DNA in cancer
cells and arrested growth, it did not induce cell death [12]. Therefore, the addition of
radiation therapy or another chemotherapeutic agent known to induce cell death may be a
more useful approach than just the treatment of Genistein alone. In a separate study using
head and neck cancer cell lines, Genistein was found to arrest the cell cycle by
upregulating Bax (pro-apoptotic agent) and p21(regulator of the cell cycle). This
mechanism helps prevent the transition to the M phase of the cell cycle as well [3].

Fig. 7 Genistein can inhibit
dysregulated cellular processes
that lead to the development of
tumors. It does this by binding to
ER-B receptors and altering the
signaling cascade.
(https://www.sciencedirect.com/s
cience/article/pii/S222541101630
0827)
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Ibrutinib (brand name: Imbruvica) is an inhibitor of Bruton’s Tyrosine Kinase,
marketed by Abbvie (previously Pharmacyclics LLC). It is used for the treatment of
white blood cell disorders such as B-cell lymphoma, chronic lymphocytic leukemia,
mantle cell lymphoma and Waldenstrom macroglobulinemia. Bruton’s Tyrosine Kinase
(BTK) operates in a pathway that regulates B-cell proliferation [14]. When mutations
occur in BTK that cause upregulation of the pathway, this can lead to the survival and
division of cancerous cells. The binding of Ibrutinib to BTK inhibits NFκB DNA
binding. This in turn decreases cell proliferation, DNA synthesis and cell survival. In
experiments using models where BTK is knocked down in mantle cell leukemia cells, the
NFκB pathway is inhibited, therefore decreasing these cells’ ability to continue to grow
and migrate [1].
In terms of GBM, Ibrutinib has shown some promise in overcoming therapy
resistance by inhibiting BMX-STAT3. This receptor is known to mediate the activity of
STAT 3, which is a transducer needed for the maintenance of glioma stem cells. These
stem cells are thought to be instrumental to the tumor’s ability to resist therapy, whether
it be chemotherapy or radiation therapy. Inhibition of this pathway by Ibrutinib decreased
gliomas stem cell- induced tumor progression/growth and in turn, was able to shrink
tumors in GSC-derived orthotopic xenografts [27]. Case Comprehensive Cancer Center is
currently conducting a clinical trial involving the use of Ibrutinib with Temozolomide
(chemotherapy commonly used to treat GBM) along with radiation therapy, in hopes of
decreasing the growth of these malignant cells [19].
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Fig. 8 Ibrutinib binds to BTK, inhibiting the
pathway important for B-cell proliferation,
differentiation and survival.(
https://clincancerres.aacrjournals.org/content/20/
21/5365)

Apatinib, also called rivoceranib, is sold under the brand name Aitan by Elevar
Therapeutics and was originally developed for the treatment of gastric cancers. Its
efficacy is currently being studied in a clinical trial for patients with either advanced or
metastatic stomach cancer across twelve different countries. It has also shown some
promise for in the treatment of hepatocellular carcinoma, colorectal carcinoma and
adenoid cystic carcinoma [7]. Apatinib is a small molecule and is taken orally in order to
inhibit vascular endothelial growth factor receptor-2. VEGFR-2 has angiogenic effects
because of its autophosphorylation at its kinase-insert region and carboxy terminal tail.
The process of angiogenesis is an important step in the development of solid tumors, so
inhibiting this mechanism may slow or stop the growth of tumors.
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Since Apatinib has shown to inhibit VEGFR-2 and subsequent downstream
phosphorylation, it was used in this screen, as angiogenesis is a driver of brain tumor
growth. In fact, gliomas are the most angiogenic of all cancerous tumor types. In gliomas,
this mechanism is both hypoxia- dependent and independent, so targeting genes
associated with hypoxia, in this case VEGF, may be a useful therapeutic approach.
Furthermore, stem cells sampled from gliomas tend to have significantly higher VEGF
levels, which is hypothesized to be the reason behind the high vessel densities measured
in gliomas [23]. In one study, Apatinib was paired with Temozolomide and administered
to patients with recurrent GBM. Even though the disease control rate was 90%, the
median overall survival was still less than one year (nine months) [36].

Alleman 13

Fig. 9 When VEGFA binds to VEGFR, a cascade is
initiated, leading to the development of new blood
vessels. This allows for the continued growth of the
tumor. Binding of Apatinib to VEGFR-2 prevents
angiogenesis.
(https://www.wjgnet.com/19485182/full/v12/i10/766.htm)

2. Materials and Methods
Drosophila with UAS PtenRNAi and UAS RasV12 mutations were crossed with each
other in order to create a new stock [UASptenRNAi; UASRasV12]. Female virgins from this
stock (as denoted by meconium in the abdomen) were crossed with males from the repoGal4 UAS-GFP stock. Virgins were collected twice a day, once in the morning and then
approximately four hours later. Depending on the amount of flies available, they were
placed in the same vial at a ratio of three males to six females or five males to ten
females. These flies were placed in a box the incubator regulated at 24 degrees Celsius.
Each morning, the flies from all stocks were flipped into new vials and labeled and dated
accordingly. The PtenRNAi;RasV12 and repo-Gal4,GFP stocks were stored at room

Alleman 14
temperature, while the glioma cross was maintained in the 25oC incubator during the
course of the study.
The Tyrosine Kinase inhibitors were added to vials containing only the fly food (the
same type of food present in the vials of all the stocks). This was performed by a graduate
student to ensure that the technique was done properly and safely. The drugs were added
to the vials at two different concentrations: 10uM and 300uM. Four separate vials were
prepared for the 10uM concentration and four for the 300uM concentration. These vials
were prepared either the day of or a few days before the addition of the larvae, and then
stored in the lab refrigerator immediately. The identity of each drug was unknown to the
students and rather denoted by letters and numbers.
The larvae that were added to the vials containing the drug came from the repo GFP
stock and the glioma stock. Approximately 20 larvae from the repo GFP stock were
added to the 10uM drug vials and then 20 larvae were added to the 300uM vials. The
same thing was done for the glioma stock as well. Additionally, when larvae were not
crawling on the sides of the vial, a small amount of water was added to the vial to get the
larvae to come up. When collecting the glioma cross, only the non-TM6B larvae were
added to the drug vials, meaning these larvae were “non-tubby.” All vials were labeled
according to the drug, the concentration and which stock was placed in the vial and dated.
These vials were then placed in a separate container in the incubator and with one repo
GFP at 10uM and one glioma cross at 10uM left to develop for five days, one repo GFP
at 10uM and one glioma cross at 10uM left to develop for six days, one repo GFP at
300uM and one glioma cross at 300um to develop for five days and one repo GFP at
300uM and one glioma cross at 300uM to develop for six days.
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After either five or six days had passed, according to how the vials were labeled,
larvae were removed and dissected. The goal was to remove enough larvae in order to
have five brains to mount on a microscope slide. Sometimes, there were no larvae
available and other times, water had to be added in order for larvae to come up. After
enough larvae were collected for dissection, they were placed on dishes in a solution of
PBS. One five and one 55 forceps were used to pull the larvae in half to remove the head
because only the brains were used for this study.
Once the larvae had been pulled apart, the portions containing the brains were placed
in an Eppendorf tube containing 150uL of PBS and 50uL of 15% PFA (well mixed) and
left to sit upright for 20 minutes. Next, 1000uL of PBST was added to the Eppendorf tube
and it was placed on a rotator for ten minutes. Then, most of the liquid was suctioned up
using a vacuum, leaving the sample at the bottom and 1000uL of PBST was added again
into the tube. It was then placed back onto the rotator for another ten minutes. This
process of vacuuming, putting more 1000uL of PBST back into the tube and placing on
the rotator was repeated two more times. After the final rotation step, the liquid was not
vacuumed up so that the sample did not dry up.
Once the sample had been properly washed, a slide was prepared for each set of
samples, which was properly labeled and dated. The tip of a pipette was cut in order to
suction up the sample and place it onto the slide. Then, using two 55 forceps, the sample
was delicately pulled apart and the debris was washed off using a Kim wipe so that only
the ventral nerve cords and the brain lobes attached were left. Once all the brains were
prepared and debris wiped away, they were pushed to the side of the slide so they could
eventually be mounted in the center. While dissecting the brains, it was important to keep
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the sample moist with PBST so it did not dry out and no longer be usable. In the center of
the slide, 10-20uL of Vectashield (depending on how many brains were dissected) was
added and the samples were lined up, one by one in the center. Excess Vectashield was
wiped away using a Kim wipe. Then, a slide cover was slowly and carefully lowered onto
the sample and held down by painting the edges with a small amount of nail polish. The
slides were then placed in a folder in the freezer for storage.
The final step of this process involves imaging the brains using fluorescent
microscopy. Each slide was placed onto the slide mount and put into focus on each
individual brain. The images were saved to a flash drive and placed in a file to study
further. The slides were then put back into the folder and placed into the freezer. The
images were analyzed according to glia cell density and the shape of the brain.

3. Results
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The following images were taken using fluorescent microscopy. The green
fluorescence indicates glia, as the GFP makes these cells glow green using this
imaging technique. Not all images of samples are included, but rather, images that
clearly exemplified the effects of the various drugs. In all cases an example of the
most represented effect is presented.

Fig. 10 Image A is a normal brain in which all glia are marked by
repo GFP, with the optic lobes that connect together to form the
Central Brain (CB) and the ventral nerve cord (VNC). Image B
depicts a brain from the glioma cross. There is an increase in glia
density and the lobes are deformed.

Fig. 11 Glioma cross day 6 treated with Saracatinib
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Fig. 15 Glioma cross day 5 (right) and day 6 (left) treated with Apatinib
Fig. 12 Glioma cross day 5 treated with Gefitinib

Fig. 13 Glioma cross day 6 treated with Genistein

Fig. 14 Glioma cross day 6 (left) and day 5 (right) treated with Ibrutinib
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4. Discussion
Overall, there was a range of effects seen in the images, indicating that the drugs
had differing strengths of inhibition. The first set of images showing the repo GFP brain
along with a glioma cross brain not treated with any drugs indicates the ways in which
the tumor changes brain structure. The tumor mishaped the brain lobes and ventral nerve
cord and also lead to an increase in glia density. This is because of the rapid division of
cancer cells.
Some of the larvae that were fed the drugs did not survive, indicating that the drug
given at that concentration was too lethal. Additionally, some larvae did not come up
until day six or even the seventh day. This indicates that the drug may have slowed
normal larvae growth and development. Further testing is needed to understand and
quantify this finding.
The tumors treated with Saracatinib resulted in brains with decreased tumor sizes.
These brains were also not deformed, but rather had wider ventral nerve cords as
compared to the repo GFP brain. Additionally, there was still a high concentration of
glia, specifically in the two lobes. Saracatinib shows promise in terms of reducing tumor
size. This effect may be due to Saracatinib’s ability to inhibit SRC as well as Fyn.
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Tumors treated with Gefitinib had some of the most significant effects. These
brains closely matched the shape of the unaffected brain, with clearly defined lobes and a
ventral nerve cord. These structures did not seem to be overly enlarged or deformed due
to tumor infiltration. However, there is still an increase in the glia density in both images.
Since Gefitinib is able to bind to and inhibit EGFR, this drug could have played a role in
slowing the division of cancerous glia or decreased cell proliferation.
Genistein showed promise as well, due to the decreased glia count in the outer
portions of the brain lobes. The brains were also not as malformed as the untreated
glioma brains. Genistein’s ability to target MAPK and PI3K/Akt pathways may have
caused this inhibition because these pathways are not well-regulated in glioma cells.
Ibrutinib also seemed to have a significant effect on the appearance of the brains,
since they were near normal size and shape as compared to the unaffected brain image.
Furthermore, the brain lobes and ventral nerve cord are clearly defined. Out of the the
drugs studied, Ibrutinib seemed to have the strongest effect on glia cell count. Ibrutinib
targets and inhibits Bruton’s Tyrosine Kinase, which could be the reason behind the
decreased tumor size and its lessened effects on the brain.
The brains treated with Apatinib were not as deformed as the untreated brains.
However, the ventral nerve cord was not shaped like the control repo GFP brain. There
was also a high density of glia throughout the brain, indicating that the cancer cells were
dividing quicker than healthy glia. These effects may be due to the fact that Apatinib is a
known VEGFR-2 inhibitor and the pathway associated with this receptor is dysregulated
in GBM.
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To summarize, these five drugs all had anti-cancer effects, as they shrunk the
tumors and/or made the brain appear more like the repoGFP brain. However, the degree
to which these drugs worked differed across the samples, indicating that some drugs were
more effective than others. Further study and a deeper analysis of these drugs at varying
concentrations is necessary in order to definitively conclude which ones may be useful in
the treatment of human brain cancer.
5. Future Directions
First of all, the next step of this study involves testing the rest of the drugs. This
will allow for more possible treatment options to study. Once all of the drugs have been
tested, it is important to determine the EC50 of the ones found to be effective in
decreasing tumor progression. This value will determine the best concentration to use the
drug. Another possible next step includes using various drugs in combination with either
each other or other drugs already used for the treatment of gliomas. This could more
closely mimic treatment protocol for glioma patients, as chemotherapy regimens often
entail a cocktail of powerful drugs. Down the road, the use of another model organism,
such as mice may be useful to model tumors as well and test the anti-angiogenic effects
of some of the drugs. This could also be a useful way to test a drug’s ability to cross the
blood-brain barrier.

The Role of p53 and E2F Mutations in Glioma Progression and Therapy Resistance

Alleman 22
Gliomas are among the most deadly types of cancers, with the median survival
after diagnosis being just 12-15 months. Although there are numerous types of gliomas
that occur in adults and children, glioblastoma multiforme (GBM) is typically the most
lethal. Patients diagnosed with this type of brain cancer often experience symptoms such
as dizziness, headaches, nausea, seizures and a multitude of other neurological issues.
Once diagnosed, the typical course of treatment includes a grueling regimen of surgery,
chemotherapy and radiation therapy. The chances of a patient surviving even one year
after diagnosis, in spite of these rigorous treatments is only 25%. The five year survival
rates are even bleaker, as only 5% of patients will live past this point [31]. Even after a
patient receives all of these therapies, the recurrence rate for GBM is extremely high.
Oftentimes, the tumor recurs in the same location it originated in and is even more
aggressive. When a patient relapses, there are even fewer therapeutic options, with most
being experimental and eventually, the disease runs its course. Because of the devastating
effects of this disease, it is critical to pursue research endeavors that will eventually
benefit patients and improve survival odds.
Gliomas are solid primary brain tumors which arise from glia. Glia constitutes the
connective tissue of the brain. These cells were originally thought to be the “glue”
holding the brain together, although research has shown that glia are much more than just
glue. Scientists are still working to grasp the roles of glia, which include modulating
neurotransmission and even performing immune functions [33]. Like any other cancer,
gliomas arise due to the rapid division of mutated cells and in this case, these cells are
glia. The exact causes and mechanisms behind these mutations are unknown.
Furthermore, the complete range of mutations found in gliomas are not fully understood.
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However, the potential that certain mutations have to propel uncontrollable cell division
is no secret. What were once a few unhealthy cells, can eventually form a large mass and
kill a person within a matter of months.
The reason that these tumors are so deadly is the fact that they are often resistant
to current therapy options. Therapy resistance refers to the ability of a cancer to no longer
respond to treatments, either chemotherapy or radiation therapy, and continue to progress.
Although the exact process of how cancer cells develop resistance is unknown, there are
many studies which point to various mechanisms playing a role. Generally, there are
changes happening at the genetic level in the cells as well as the tumor
microenvironment. GBM cells are heterogeneous by nature, which points toward the cells
having developed mechanisms to evade the body’s way of destroying mutated cells. This
heterogeneity results from the selection/adaptation processes happening in developing
cancers [38].
Another contributor to therapy resistance in GBM is the different morphology of
endothelial cells lining the blood vessels providing blood flow to the tumor. Interestingly,
brain tumors have significantly higher blood vessel densities as compared to tumors in
other parts of the body. Some types of brain tumors have blood vessel densities which are
50% higher than tumors in other locations. The mutated endothelial cells in GBM are
able to migrate quicker and have a higher number of growth factors, which allow them to
continue to support the growing tumor. The fact that these endothelial cells contain
abnormal centromeres is believed to be a key player in preventing a proper response to
therapy [37].
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These same types of cells compose the blood brain barrier, which poses its own
difficulty in delivering drugs to the brain. Although this mechanism works to protect the
brain from infections and toxins, it also prevents the entry of many chemotherapeutic
agents into the brain environment. New advances in nanotechnology aim to evade the
blood brain barrier in order to deliver drugs to the brain, not only for the treatment of
cancer, but many other neurological conditions [13]. The blood brain barrier is disturbed
in GBM patients, which causes edema and increased pressure in the brain, which has the
potential to damage remaining healthy tissue. Issues with the polarity of astrocytes are
hypothesized to be reason that the blood brain barrier tends to be disturbed in cases of
GBM [37].
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One major reason that these tumors are often resistant to therapies lies within the
cancer cells themselves. There are a plethora of oncogenic mutations causing these cells
to proliferate and divide uncontrollably. There are many known mutations, such as EGFR
and IDH known to play a role in therapy resistance. EGFR, which has amplified activity
in 40-60% of GBM cases, may respond positively to chemotherapies that target this
mutation initially. However, due to unknown mechanisms, new mutations arise which
make the cancer cells resistant to this therapy, causing the tumor to grow yet again.
Patients with IDH mutations tend to fare slightly better than those with IDH wildtype.
Although there are multiple types of IDH mutations, they eventually result in an increase
in onco-metabolite d-2-hydroxy-glutarate, which in turn leads to oxidative stress and
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eventually the damage of once healthy DNA [17]. Wildtype IDH is a marker for
resistance to chemotherapy, as IDH mutants have shown reduced proliferation as
compared to the wildtype [35]. In terms of radiation therapy, one mutation that
contributes to this is ASAH1, which becomes upregulated after being exposed to
radiation treatments, aiding in the proliferation of cancerous cells [17].
This project hinges on the fact that there are numerous mutations within GBM
cells that make the cancer both difficult to treat and resistant to current therapies. This
endeavor involved testing the effects of a p53 mutation and an E2F mutation on glioma
progression. Certain p53 gain of function mutations result in a decreased response to
Temozolamide (common GBM drug) and therefore, may be a marker for therapy
resistance [20].
The reason for incorporating an E2F mutation into this experiment is because E2F
operates in the same pathway as p53 and helps to regulate its activity. The way in which
this experiment addresses the issue of therapy resistance is by testing two mutations, p53
and E2F, as possible contributors to the aggressive nature of the tumor. Subsequently,
running models with these mutations through a slew of different chemicals may identify
possible drugs which target them. The overarching goal of this project is to gain a better
understanding of the cellular and biochemical defects occurring in these tumors in an
effort to eventually improve outcomes for patients. Once targets are identified, treating a
patient with drugs that combat certain mutations can more effectively treat their cancer.
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When functioning normally, the TP53 gene (on chromosome 17) acts as a tumor
suppressor and is nicknamed the “guardian of the genome.” TP53 works by coding for
p53 proteins which bind to DNA, targeting the CDKN1A gene (on chromosome 6) to
make the protein p21. This protein complexes with cdk2, which is a protein that
stimulates cell division. Once this complex forms, the cell does not move forward in
mitosis, essentially halting cell division [15]. This includes stopping division of mutated
cells which may be cancerous. An issue with this pathway can lead to a disastrous
hallmark of cancer: uncontrollable division of mutated cells.

A mutation within p53 can have serious consequences for a patient, because it
disrupts this important cellular process. A p53 gene mutation leads to the translation of
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mutated p53 proteins. Not only do these proteins improperly bind to DNA and fail to
control cell division, but they also develop oncogenic properties. High levels of these
proteins are often found in cancer cells of various types. When functioning as an
oncogene, p53 helps sustain the survival of mutated cells. Therefore, mutations which
inactivate p53 contribute to tumorigenesis and eventually metastasis in many types of
cancers. Interestingly, mutant p53 can inactivate wildtype p53, although not always
completely. The dominant negative mechanism of mutant p53 renders the healthy allele
unable to perform its usual functions [25]. The exact cause of these mutations in GBM
patients remains unknown.
Evidence for the importance of p53 is seen in people without two working copies
of this gene. Individuals with Li Fraumeni syndrome have only one functional copy of
p53 inherited from one parent. This causes a predisposition to cancer because, if the only
copy of p53 is damaged, the affected cells lose their ability to properly regulate cell
division. This is why nearly half of all people with Li Fraumeni syndrome will develop
cancer before the age of 30 and 80% will be diagnosed before the age of 60. One organ in
which people with Li Fraumeni syndrome commonly develop cancer is the brain, further
implicating the way p53 mutations cause progression of brain tumors [30].
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Deregulation of the p53 pathway is seen in 84% of GBM patients, indicating the
vast impact of p53 mutations in the development and progression of GBM. Evidence of
p53 mutations in astrocytomas and low-grade gliomas suggest that these mutations are
early events in tumorigenesis. In addition to damaging a major apoptotic pathway, p53
point mutations promote the gain of function of oncogenic variations of p53 proteins.
This is what promotes malignancy in gliomas, since they begin to work as transcription
factors [39]. p53 mutations are thought to be the reason behind certain gliomas’
resistance to Temozolamide. This is because inactivation of p53 promotes the activity of
the DNA repair enzyme, MGMT [8]. Furthermore, p53 promotes inflammation in
gliomas, making patients’ prognoses even more dismal [9].Because of these events, it is
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necessary to identify treatments that can either destroy mutated p53 or help restore its
original tumor suppressor abilities.

It is important to recognize that p53 does not operate independently, but rather is
mediated by E2F. One author described the relationship between p53 and E2F as
“partners in life and death” [22]. The Rb–E2f and MDM2–p53 pathways are deregulated
in a majority of tumors and operate independently. However, when E2F and p53 function
as transcription factors, they facilitate crosstalk between these two pathways [22]. When
E2F1 is overexpressed, it activates p53 in response, which in turn begins the signaling
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cascade which leads to apoptosis [11]. Hence, E2F acts as a tumor suppressor and is an
important factor to consider when studying p53.
E2F has been shown to induce apoptosis in p53-dependent and independent
manners. Although the exact mechanisms for p53-dependent apoptosis are not fully
understood, there are several theories. One such theory suggests that by targeting the
p14(p19)/Arf tumor suppressor gene, E2F induces stability of p53. Further studies have
shown that E2F still affects p53 in the absence of Arf, suggesting there are other routes in
which E2F functions. Another theory proposes that, in response to DNA damage, the
cyclin A-binding domain present in E2F interacts with p53. This interaction stabilizes
p53. There are also two hypotheses for the way in which E2F triggers apoptosis
independent of activity with p53. E2F is thought to accomplish this by either interacting
with p73 (a transcription factor, part of the p53 family) or by working with the tumor
necrosis factor [5,26].
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The transcription factors associated with E2F work to regulate genes important
for various stages of the cell cycle, specifically, the G1 and S phases. This acts as a way
to control cell division. When E2F genes are improperly expressed, cells continue to
enter the S phase, unchecked and then begin to divide [10]. E2F has dueling abilities to
both activate and repress transcription, so when mutated, it can function as an oncogene.
When not mutated, E2F1 plays a role in responding to damaged DNA, as heightened
levels of this protein have been detected in cells that had been given chemicals known to
cause DNA damage [5]. Although the direct cause of mutations in the E2F family of
genes in GBM is not known, E2F is regulated by the pRB family of proteins [6].
Therefore, dysregulation of this pathway may be partially to blame for the oncogenic
effects of E2F.
Due to the well-established relationship between E2F and p53 and their known
role as oncogenes, this project seeks to understand how mutations in these genes
contribute to gliomas. The plan for this project was to induce both of these mutations into
Drosophila in addition to the tumor-driving PtenRNAi ; RasV12 mutation used in the drug
screen. In order to induce a p53 mutation, a dominant negative approach was put into
place. The E2F mutation was to be added by using an RNA interference approach to
knock-down dE2F1. By creating a triple mutant, expressing these specific mutations, we
would have a more complete model of human brain tumors. Testing how these tumors
grow and progress would give insight into the way these mutations affect this process.
Testing these mutants with various Tyrosine Kinase inhibitors would assess them for
therapy resistance and hopefully identify agents which target these mutations.
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Although the clear goal was established and a detailed plan of how to achieve it
was devised, it was not fully realized. Due to contaminated fly food, many stocks died.
At one point the project was restarted because the stocks did not survive. Once the project
got back on its feet and started moving smoothly, the COVID-19 shutdown stopped all
undergraduate research for the spring 2020 and fall semester. Therefore we have
preliminary data to present, but no information regarding the tumor progression data and
response to various drugs.
Results:
Fig.19

Fig. 20
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Even though this project remains unfinished, preliminary data points to this
approach serving as a viable method for creating the triple mutants. The balancer stocks
were healthy and viable. We are hopeful that in the future, other undergraduate lab
members will be interested in understanding the role of p53 and E2F in gliomas and pick
up where we left off.
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